Consolidated Statement of Stockholders' Equity (USD $)	Total	Common stock issued @ $5.86	Common stock issued @ $18.95	Preferred stock issued @ $1,000 per share	Common Stock Issued to Galloway	Common Stock	Common Stock Common stock issued @ $5.86	Common Stock Common stock issued @ $18.95	Common Stock Common Stock Issued to Galloway	Preferred Stock	Preferred Stock Preferred stock issued @ $1,000 per share	Additional Paid-in Capital	Additional Paid-in Capital Common stock issued @ $5.86	Additional Paid-in Capital Common stock issued @ $18.95	Additional Paid-in Capital Preferred stock issued @ $1,000 per share	Additional Paid-in Capital Common Stock Issued to Galloway	Accumulated Deficit	Non-controlling Interest
Beginning Balance Amount at Sep. 30, 2013	$ 25,734,789					$ 124,859				$ 10		$ 193,514,766					$ (166,140,969)	$ (1,763,877)
Beginning Balance Shares at Sep. 30, 2013						32,489,444				9,900
Exercise of warrants						2,875,727
Exercise of warrants, Amount	10,004,793					2,875						10,001,918
Stock options exercised	377,112					377,112
Stock options exercised, Amount	2,369,262					377						2,368,885
Stock-based compensation	3,758,264											3,758,264
Stock issuances, Shares							3,071,672	6,325,000	131,579		46,000
Stock issuances		14,060,112	112,581,559	46,000,000	500,000		3,072	6,325	132		46		14,057,040	112,575,234	45,999,954	499,868
Settlements related to derivative liability	5,789,979											5,789,979
Preferred stock converted to common stock, Shares						7,638,033				(34,609)
Preferred stock converted to common stock						7,638				(35)		(7,603)
Deconsolidation of Calando Pharmaceuticals, Inc.	1,303,911																	1,303,911
Net loss for the nine months ended June 30, 2014	(36,294,880)																(36,199,748)	(95,132)
Ending Balance Amount at Jun. 30, 2014	$ 185,807,789					$ 145,278				$ 21		$ 388,558,305					$ (202,340,717)	$ (555,098)
Ending Balance Shares at Jun. 30, 2014						52,908,567				21,291